Professor Zhang Huilai commented on the list. CAR-T therapy was approved: bring more clinical benefits to Chinese patients

On July 1, the "Top Ten Progress in the Cancer Field of the Public Public Most Incurities in 2021" was launched in "I do practical practice activities for the masses · Healthy Chinese Oncology Prevention and Control (2022-2023) and" Tumor's Things "column launched The launching ceremony was officially released.

(The above comments are from Zhang Huilai's professor of the China Anti -Cancer Association lymphatic and Slimming Committee Deputy Chairman of the Customs Committee, Director of the Department of lymphoma in the Department of lymphoma in the Cancer Hospital of Tianjin Medical University)

In the past, research data at home and abroad showed that the median survival time of patients with difficulty governing large B-cell lymphoma (DLB-CL) was only about 6 months, but with immunotherapy, especially chimeric antigen receptor T cell therapy (CAR -T-theal therapy) has significantly improved the prognosis of the crowd. The latest data shows that the 5-year survival rate of patients with CAR-T the treatment of CAR-T treatment can reach 42.6%.

In 2021, my country officially ushered in the first year of cellular immunity.

This year, there were two CAR-T products Aquelun Said injections and Rockyo Lenn injections were approved to be listed in China, providing a new treatment choice and new cure for patients with dilin DLBCL patients. It has attracted widespread social attention. However, due to the large investment investment in the early stage, the preparation of high individualization and high cost of consumables, the current CAR-T treatment costs are as high as one million, which greatly restricts its widespread clinical application. It is believed that with the advancement of CAR-T technology and the continuous improvement of the national and local medical security systems, especially the addition of commercial insurance, the availability and safety of CAR-T products will become better and better, so as to truly benefit our vast number of tumors patient.

- END -